Visceral fat is better related to impaired glucose metabolism than body mass index after kidney transplantation

Transplant International

Volumn 28, Issue 10, 2015, Pages 1162-1171

  Von Düring, Marit Elizabeth ^a,b   Jenssen, Trond ^a,c   Bollerslev, Jens ^a,b   Åsberg, Anders ^a,d   Godang, Kristin ^a   Eide, Ivar Anders ^a,b   Dahle, Dag Olav ^a,b   Hartmann, Anders ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c UNIVERSITY OF TROMSØ   (Norway)

^d UNIVERSITY OF OSLO   (Norway)

Author keywords

HOMA IR index; insulin resistance; kidney transplantation; new onset diabetes mellitus; post transplant diabetes mellitus; visceral fat

Indexed keywords

BASILIXIMAB; CYCLOSPORIN; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN; METHYLPREDNISOLONE; MYCOPHENOLATE MOFETIL; PREDNISOLONE; RITUXIMAB; TACROLIMUS; GLUCOSE BLOOD LEVEL; IMMUNOSUPPRESSIVE AGENT; INSULIN; LIPID;

ADULT; AGED; ARTICLE; BODY MASS; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DIET RESTRICTION; DISORDERS OF CARBOHYDRATE METABOLISM; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IMPAIRED FASTING GLUCOSE; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; INTRAABDOMINAL FAT; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; ORAL GLUCOSE TOLERANCE TEST; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; ANALYSIS; BLOOD; BODY COMPOSITION; CHEMICALLY INDUCED; DONOR; GLUCOSE TOLERANCE TEST; METABOLISM; MIDDLE AGED; PHOTON ABSORPTIOMETRY; POSTOPERATIVE COMPLICATIONS; RADIOGRAPHY;

ABSORPTIOMETRY, PHOTON; ADULT; AGED; BLOOD GLUCOSE; BODY COMPOSITION; BODY MASS INDEX; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS; GLUCOSE; GLUCOSE TOLERANCE TEST; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSIVE AGENTS; INSULIN; INSULIN RESISTANCE; INTRA-ABDOMINAL FAT; KIDNEY TRANSPLANTATION; LIPIDS; METHYLPREDNISOLONE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PREDNISOLONE; RITUXIMAB; TISSUE DONORS;

EID: 84940795250     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/tri.12606     Document Type: Article

References (44)

1. Valderhaug TG, Hjelmesaeth J, Jenssen T, Roislien J, Leivestad T, Hartmann A,. Early posttransplantation hyperglycemia in kidney transplant recipients is associated with overall long-term graft losses. Transplantation 2012; 94: 714.
2. Cosio FG, Kudva Y, van der Velde M, et al,. New onset hyperglycemia and diabetes are associated with increased cardiovascular risk after kidney transplantation. Kidney Int 2005; 67: 2415.
3. Wauters RP, Cosio FG, Suarez FM, Kudva Y, Shah P, Torres VE,. Cardiovascular consequences of new-onset hyperglycemia after kidney transplantation. Transplantation 2012; 94: 377.
4. Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ,. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003; 3: 178.
5. Cole EH, Johnston O, Rose CL, Gill JS,. Impact of acute rejection and new-onset diabetes on long-term transplant graft and patient survival. Clin J Am Soc Nephrol 2008; 3: 814.
6. Sharif A, Hecking M, de Vries AP, et al,. Proceedings from an international consensus meeting on posttransplantation diabetes mellitus: recommendations and future directions. Am J Transplant 2014; 14: 1992.
7. Sarno G, Muscogiuri G, De Rosa P,. New-onset diabetes after kidney transplantation: prevalence, risk factors, and management. Transplantation 2012; 93: 1189.
8. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2012; 35 (Suppl. 1): S64.
9. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2014; 37 (Suppl. 1): S81.
10. Dong M, Parsaik AK, Eberhardt NL, Basu A, Cosio FG, Kudva YC,. Cellular and physiological mechanisms of new-onset diabetes mellitus after solid organ transplantation. Diabet Med 2012; 29: e1.
11. Hjelmesaeth J, Asberg A, Muller F, Hartmann A, Jenssen T,. New-onset posttransplantation diabetes mellitus: insulin resistance or insulinopenia? Impact of immunosuppressive drugs, cytomegalovirus and hepatitis C virus infection. Curr Diabet Rev 2005; 1: 1.
12. Hjelmesaeth J, Midtvedt K, Jenssen T, Hartmann A,. Insulin resistance after renal transplantation: impact of immunosuppressive and antihypertensive therapy. Diabetes Care 2001; 24: 2121.
13. Bayer ND, Cochetti PT, Anil Kumar MS, et al,. Association of metabolic syndrome with development of new-onset diabetes after transplantation. Transplantation 2010; 90: 861.
14. Chakkera HA, Weil EJ, Swanson CM, et al,. Pretransplant risk score for new-onset diabetes after kidney transplantation. Diabetes Care 2011; 34: 2141.
15. Tchernof A, Despres JP,. Pathophysiology of human visceral obesity: an update. Physiol Rev 2013; 93: 359.
16. Kim SJ, Chae S, Kim H, et al,. A protein profile of visceral adipose tissues linked to early pathogenesis of type 2 diabetes mellitus. Mol Cell Proteomics 2014; 13: 811.
17. Fontana L, Eagon JC, Trujillo ME, Scherer PE, Klein S,. Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. Diabetes 2007; 56: 1010.
18. Boyko EJ, Fujimoto WY, Leonetti DL, Newell-Morris L,. Visceral adiposity and risk of type 2 diabetes: a prospective study among Japanese Americans. Diabetes Care 2000; 23: 465.
19. Sharif A, Moore R, Baboolal K,. Influence of lifestyle modification in renal transplant recipients with postprandial hyperglycemia. Transplantation 2008; 85: 353.
20. Silver HJ, Welch EB, Avison MJ, Niswender KD,. Imaging body composition in obesity and weight loss: challenges and opportunities. Diabetes Metab Syndr Obes 2010; 3: 337.
21. Brenner DJ, Hall EJ,. Computed tomography-an increasing source of radiation exposure. N Engl J Med 2007; 357: 2277.
22. Micklesfield LK, Goedecke JH, Punyanitya M, Wilson KE, Kelly TL,. Dual-energy X-ray performs as well as clinical computed tomography for the measurement of visceral fat. Obesity 2012; 20: 1109.
23. Sam S, Haffner S, Davidson MH, et al,. Relation of abdominal fat depots to systemic markers of inflammation in type 2 diabetes. Diabetes Care 2009; 32: 932.
24. Valderhaug TG, Hjelmesaeth J, Rollag H, et al,. Reduced incidence of new-onset posttransplantation diabetes mellitus during the last decade. Transplantation 2007; 84: 1125.
25. Valderhaug TG, Hjelmesaeth J, Hartmann A, et al,. The association of early post-transplant glucose levels with long-term mortality. Diabetologia 2011; 54: 1341.
26. Rustad P, Felding P, Franzson L, et al,. The Nordic Reference Interval Project 2000: recommended reference intervals for 25 common biochemical properties. Scand J Clin Lab Invest 2004; 64: 271.
27. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC,. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412.
28. American Diabetes Association. Standards of medical care in diabetes-2010. Diabetes Care 2010; 33 (Suppl. 1): S11.
29. Mazess RB, Barden HS, Bisek JP, Hanson J,. Dual-energy x-ray absorptiometry for total-body and regional bone-mineral and soft-tissue composition. Am J Clin Nutr 1990; 51: 1106.
30. Ergun DL, Rothney MP, Oates MK, Xia Y, Wacker WK, Binkley NC,. Visceral adipose tissue quantification using Lunar Prodigy. J Clin Densitom 2013; 16: 75.
31. Olarescu NC, Jorgensen AP, Godang K, Jurik AG, Froslie KF, Bollerslev J,. Dual-energy X-ray absorptiometry is a valid method to estimate visceral adipose tissue in adult patients with Prader-Willi syndrome during treatment with growth hormone. J Clin Endocrinol Metab 2014; 99: E1727.
32. Wang Y, Rimm EB, Stampfer MJ, Willett WC, Hu FB,. Comparison of abdominal adiposity and overall obesity in predicting risk of type 2 diabetes among men. Am J Clin Nutr 2005; 81: 555.
33. Tchernof ADJ,. Pathophysiology of human visceral obesity: an update. Physiol Rev 2013; 93: 359.
34. Bayes B, Granada ML, Pastor MC, et al,. Obesity, adiponectin and inflammation as predictors of new-onset diabetes mellitus after kidney transplantation. Am J Transplant 2007; 7: 416.
35. Asayama K, Hayashibe H, Dobashi K, et al,. Decrease in serum adiponectin level due to obesity and visceral fat accumulation in children. Obes Res 2003; 11: 1072.
36. Barzilai N, She L, Liu BQ, et al,. Surgical removal of visceral fat reverses hepatic insulin resistance. Diabetes 1999; 48: 94.
37. Foster MT, Shi H, Seeley RJ, Woods SC,. Removal of intra-abdominal visceral adipose tissue improves glucose tolerance in rats: role of hepatic triglyceride storage. Physiol Behav 2011; 104: 845.
38. Kim YW, Kim JY, Lee SK,. Surgical removal of visceral fat decreases plasma free fatty acid and increases insulin sensitivity on liver and peripheral tissue in monosodium glutamate (MSG)-obese rats. J Korean Med Sci 1999; 14: 539.
39. Castro AV, Woolcott OO, Iyer MS, et al,. Increase in visceral fat Per Se does not induce insulin resistance in the canine model. Obesity 2015; 23: 105.
40. Gastaldelli A, Sironi AM, Ciociaro D, et al,. Visceral fat and beta cell function in non-diabetic humans. Diabetologia 2005; 48: 2090.
41. Hecking M, Kainz A, Werzowa J, et al,. Glucose metabolism after renal transplantation. Diabetes Care 2013; 36: 2763.
42. Naboush A, Hamdy O,. Measuring visceral and hepatic fat in clinical practice and clinical research. Endocr Pract 2013; 19: 587.
43. Ibanez J, Izquierdo M, Arguelles I, et al,. Twice-weekly progressive resistance training decreases abdominal fat and improves insulin sensitivity in older men with type 2 diabetes. Diabetes Care 2005; 28: 662.
44. Gallagher D, Heshka S, Kelley DE, et al,. Changes in adipose tissue depots and metabolic markers following a 1-year diet and exercise intervention in overweight and obese patients with type 2 diabetes. Diabetes Care 2014; 37: 3325.